Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer – Forbes
Forbes |
Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer
Forbes That cash is a launch pad for a business that aims to be a successor to the hottest biotech companies around today: CAR-T companies like Juno Therapeutics (just sold to Celgene for $9 billion) and Kite Pharmaceuticals (sold to Gilead last year for $11 … Peter Diamandis Is the Latest Tech Futurist Betting on Stem Cells A startup that wants to use stem cells to keep us living longer just raised $250 million |
